DE60040753D1 - Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden - Google Patents
Therapeutische verwendungen von steroiden bei blutzellmangelzustaendenInfo
- Publication number
- DE60040753D1 DE60040753D1 DE60040753T DE60040753T DE60040753D1 DE 60040753 D1 DE60040753 D1 DE 60040753D1 DE 60040753 T DE60040753 T DE 60040753T DE 60040753 T DE60040753 T DE 60040753T DE 60040753 D1 DE60040753 D1 DE 60040753D1
- Authority
- DE
- Germany
- Prior art keywords
- exposures
- steroids
- blood cell
- therapeutic uses
- cell fault
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 210000000601 blood cell Anatomy 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- CXGDRQWRJUSSAR-FLLVRBHTSA-N (5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C(C(C[C@H]43)O)O)C)[C@]2(CC1)C CXGDRQWRJUSSAR-FLLVRBHTSA-N 0.000 abstract 1
- DBJXJRIEZQPLSN-DXWCMRTCSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,7,16,17-tetrol Chemical compound C1C(O)CC[C@]2(C)[C@H]3CC[C@](C)(C(C(O)C4)O)[C@@H]4[C@@H]3C(O)C=C21 DBJXJRIEZQPLSN-DXWCMRTCSA-N 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 206010043554 thrombocytopenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0025—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16145399P | 1999-10-25 | 1999-10-25 | |
| PCT/US2000/026771 WO2001030802A2 (en) | 1999-10-25 | 2000-09-28 | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60040753D1 true DE60040753D1 (de) | 2008-12-18 |
Family
ID=22581233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60040753T Expired - Lifetime DE60040753D1 (de) | 1999-10-25 | 2000-09-28 | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1223941B1 (enExample) |
| JP (1) | JP2003512474A (enExample) |
| AT (1) | ATE413179T1 (enExample) |
| AU (3) | AU782736B2 (enExample) |
| CA (1) | CA2388939C (enExample) |
| DE (1) | DE60040753D1 (enExample) |
| WO (1) | WO2001030802A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20070129282A1 (en) | 1998-11-24 | 2007-06-07 | Ahlem Clarence N | Pharmaceutical treatments and compositions |
| US20060079492A1 (en) | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
| AU7736300A (en) | 1999-09-30 | 2001-04-30 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
| US7163918B2 (en) | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
| JP2004537506A (ja) * | 2001-03-01 | 2004-12-16 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 血液細胞欠乏症を治療するためのある種のステロイドの使用 |
| WO2004019953A1 (en) * | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| CA2522784C (en) | 2003-04-01 | 2012-06-19 | Hollis-Eden Pharmaceuticals, Inc. | Antiandrogens with marginal agonist activity and methods of use |
| US7910755B2 (en) | 2004-09-29 | 2011-03-22 | Harbor Biosciences, Inc. | Stem cell expansion and uses |
| AU2005330504B2 (en) * | 2004-09-29 | 2010-10-28 | Harbor Biosciences, Inc. | Steroid analogs and characterization and treatment methods |
| JP4839021B2 (ja) * | 2005-06-10 | 2011-12-14 | 国立大学法人 岡山大学 | 白血球及び／又は造血幹・前駆細胞動員剤 |
| US8354396B2 (en) | 2006-11-17 | 2013-01-15 | Harbor Therapeutics, Inc. | Drug identification and treatment method |
| US8217025B2 (en) | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| US8486926B2 (en) | 2006-11-17 | 2013-07-16 | Harbor Therapeutics, Inc. | Steroid tetrol solid state forms |
| CA2728889C (en) | 2008-04-03 | 2016-06-14 | Harbor Biosciences, Inc. | Solid state forms of a pharmaceutical |
| DK2300489T3 (en) | 2008-06-06 | 2016-02-15 | Neurmedix Inc | PROCESSES FOR PREPARING 17-alkynyl-7-HYDROXY STEROIDS AND RELATED COMPOUNDS |
| EP2334686B1 (en) | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Cortistatin analogues and syntheses therof |
| CN104349785A (zh) * | 2012-03-21 | 2015-02-11 | 达纳-法伯癌症研究所有限公司 | 人淋巴系器官源性抑制性基质细胞的分离和用途 |
| SG11201605178WA (en) | 2013-12-24 | 2016-07-28 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10836788B2 (en) | 2019-02-05 | 2020-11-17 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL99772C (enExample) * | ||||
| US4602008A (en) * | 1984-12-14 | 1986-07-22 | Progenics, Inc. | Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| ATE243998T1 (de) * | 1995-10-12 | 2003-07-15 | Supergen Inc | Liposomformulierung von 5-beta steroiden |
| AU718232B2 (en) * | 1995-11-13 | 2000-04-13 | Supergen, Inc. | Improved formulation for administration of steroid compounds |
| GB9708716D0 (en) * | 1997-04-29 | 1997-06-18 | Imperial College | Chronic heart failure |
| ATE269086T1 (de) * | 1998-03-06 | 2004-07-15 | Univ Brigham Young | Antibiotische steroidderivate |
-
2000
- 2000-09-28 EP EP00970511A patent/EP1223941B1/en not_active Expired - Lifetime
- 2000-09-28 AU AU79880/00A patent/AU782736B2/en not_active Ceased
- 2000-09-28 JP JP2001533153A patent/JP2003512474A/ja active Pending
- 2000-09-28 AT AT00970511T patent/ATE413179T1/de not_active IP Right Cessation
- 2000-09-28 WO PCT/US2000/026771 patent/WO2001030802A2/en not_active Ceased
- 2000-09-28 CA CA002388939A patent/CA2388939C/en not_active Expired - Fee Related
- 2000-09-28 DE DE60040753T patent/DE60040753D1/de not_active Expired - Lifetime
-
2005
- 2005-11-23 AU AU2005237117A patent/AU2005237117B2/en not_active Ceased
-
2008
- 2008-12-04 AU AU2008255138A patent/AU2008255138B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2388939A1 (en) | 2001-05-03 |
| JP2003512474A (ja) | 2003-04-02 |
| AU2008255138A2 (en) | 2009-01-15 |
| AU2008255138A1 (en) | 2009-01-08 |
| AU2005237117A1 (en) | 2005-12-15 |
| AU2005237117B2 (en) | 2008-09-04 |
| AU2008255138B2 (en) | 2011-02-24 |
| EP1223941B1 (en) | 2008-11-05 |
| ATE413179T1 (de) | 2008-11-15 |
| WO2001030802A3 (en) | 2002-02-14 |
| EP1223941A2 (en) | 2002-07-24 |
| CA2388939C (en) | 2009-06-09 |
| AU2008255138A8 (en) | 2011-10-20 |
| AU7988000A (en) | 2001-05-08 |
| AU782736B2 (en) | 2005-08-25 |
| WO2001030802A2 (en) | 2001-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE413179T1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| ATE212351T1 (de) | Androsten-derivate | |
| ATE393831T1 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
| IL151371A (en) | Modified porcine factor viii and pharmaceutical compositions containing the same | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| ATE383169T1 (de) | Komponente und zusammensetzungen zur verabreichung von wirkstoffen | |
| NO971889D0 (no) | Forbindelser og sammensetninger for levering av aktive midler | |
| CY2473B1 (en) | New phenanthridines. | |
| CY1107467T1 (el) | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων | |
| BR9406080A (pt) | Compostos que tem tanto antividade de anaonista potente de calcio como de antioxidante e uso dos mesmos como agentes citoprotetores | |
| FI972086A7 (fi) | Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset | |
| DK0752842T3 (da) | Præparater med forbedret stabilitet til kunstig solbruning | |
| BR9911040A (pt) | 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos | |
| ES2195382T3 (es) | Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos. | |
| DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
| ATE381327T1 (de) | Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis | |
| IT1269185B (it) | Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2 | |
| ATE199641T1 (de) | Terpenderivate (sarcodictyine) als antikrebsmittel | |
| ES2133918T3 (es) | Nuevos esteroides seco-d activos en el sistema cardiovascular y composiciones farmaceuticas que los contienen. | |
| PT862454E (pt) | Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados | |
| ATE212231T1 (de) | Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie | |
| GEP20032975B (en) | Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition | |
| IL125297A0 (en) | Compositions including calcium influx blockers for inhibiting cell growth | |
| BR0002640A (pt) | Uso de simeticona para tratar colite ulcerativa | |
| BR0016646A (pt) | Método para tratar um paciente que sofre de dor, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC |